NCM·Healthcare·$315M·#400 / 520 in Healthcare
AVTX Avalo Therapeutics, Inc.
28HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY60
STABILITY37
VALUATION0
GOVERNANCE14
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-86.6%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
100.0%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
4 months
6
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.5%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
5328.2x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-123688
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
2.6%
21
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+110.5%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE AVTX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when AVTX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.